Skip to main content

Search

Case Studies Winter 2024

Case study reports produced by students in UCI Anthro25A, "Environmental Injustice," in Winter 2024.

FIELDNOTE MAR 29 2023

We started our time at Naluwan with some morning dance moves to warm up our bodies. It was pleasant to see the elders actively participating in the exercise.

Fieldnote Apr 12 2023 - 1:34pm

For this visit, Juanjuan and I were grouped with five grandmothers, three from the previous visit and two new grandmothers due to the absence of our classmates.

Fieldnote Feb 21 2023 - 10:56pm

Driving through the small alley of the place where the Amis live felt odd as the modern view on my left - wind turbines, bridges, was a vast contrast from the view on my right which saw village-lik

pece_annotation_1473995548

tamar.rogoszinski
  1. I first looked up travel to and from Liberia during the Ebola outbreak, since it had been seized. There was a ban, which has since been lifted after, but people coming to and from West Africa are still screened and recommended to visit physicians. As of mid-2015 there wa still a 21 day monitoring period needed. http://www.infectioncontroltoday.com/news/2015/05/cdc-downgrades-travel…'
  2. I was interested if there had been any progress on treatment for Ebola, but found that the main form of treatment is supportive care. Doctors are informed to provide IV fluid and ensure that the patient's immune response and other bodily functions are functioning properly. A vaccine is being worked on but has not gone through a trial to prove safety and effectiveness. https://www.cdc.gov/vhf/ebola/treatment/index.html
  3. I looked further into the vaccine being produced for Ebola. Currently, there is a combined phase 2 and phase 3 trial occurring in Sierra Leone called STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola). The study is unblinded, so patients know whether or not they have received the vaccine. The vaccine is a rVSV-ZEBOV, or recombinant Vesicular Stomatitis Virus Zaire ebolavirus vaccine. This vaccine is also being used in phase 2 and phase 3 trials in Guinea and Liberia http://www.cdc.gov/vhf/ebola/strive/qa.html